Press release
Keros Therapeutics Presents Results from a Preclinical Study of RKER-012 in Pulmonary Arterial Hypertension at the American Thoracic Society International Conference
LEXINGTON, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical
About this update from Keros Therapeutics, Inc.
[{"type":"text","content":"LEXINGTON, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need, today announced results from a preclinical study of RKER-012 on pulmonary arterial pressure and right ventricle hypertrophy in an established rodent model of pulmonary arterial hypertension (“PAH”) at the American Thoracic Society (“ATS”) International Conference held May 13 through 18, 2022. Additional data from a separate nonclinical study in cynomolgus monkeys was also included in the presentation. RKER-012 prevented increased pulmonary arterial pressure and right ventricle hypertrophy in a rodent PAH model and KER-012 did not alter red blood cell number in non-human primates. RKER-012 Therapy Prevented Increased Pulmonary Arterial Pressure And Right Ventricle Hypertrophy In A Rat Model Of PAH Keros combined administration of SUGEN5416, a tyrosine kinase inhibitor of vascular endothelial growth factor receptors 1/2, with exposure to chronic hypoxia to recapitulate the biology in PAH. A research form of KER-012 (“RKER-012”) was tested in this SUGEN/hypoxia (“SH”) rat model of PAH. Adult male rats were subjected to SH and received either vehicle, 10 mg/kg of activin receptor type IIA-Fc (“ActRIIA-Fc”) or 10 mg/kg RKER-012 twice weekly for three weeks. Rats maintained under normal oxygen conditions (“normoxic controls”) received only vehicle. Consistent with the development of cardiac and pulmonary impairment, vehicle-treated SH rats exhibited increases in Fulton index, which measures enlargement of the right ventricle (p","length":2151,"tagName":"div"}]